The Influence of Disparities on Prostate Cancer at Diagnosis in the Charlotte Metropolitan Area.
Artificial intelligence
Disparities
Prostate cancer
Race
Socioeconomic status
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
30 Jul 2024
30 Jul 2024
Historique:
received:
05
03
2024
accepted:
11
06
2024
medline:
31
7
2024
pubmed:
31
7
2024
entrez:
30
7
2024
Statut:
aheadofprint
Résumé
Prostate cancer (PCa) is the most diagnosed noncutaneous malignancy and second leading-cause of cancer death in men, yet screening is decreasing. As PCa screening has become controversial, socioeconomic disparities in PCa diagnosis and outcomes widen. This study was designed to determine the current disparities influencing PCa diagnosis in Charlotte, NC. The Levine Cancer Institute database was queried for patients with PCa, living in metropolitan Charlotte. Socioeconomic status (SES) was determined by the Area Deprivation Index (ADI); higher ADI indicated lower SES. Patients were compared by their National Comprehensive Cancer Network risk stratification. Artificial intelligence predictive models were trained and heatmaps were created, demonstrating the geographic and socioeconomic disparities in late-stage PCa. Of the 802 patients assessed, 202 (25.2%) with high-risk PCa at diagnosis were compared with 198 (24.7%) with low-risk PCa. High-risk PCa patients were older (69.8 ± 9.0 vs. 64.0 ± 7.9 years; p < 0.001) with lower SES (ADI block: 98.4 ± 20.9 vs. 92.1 ± 19.8; p = 0.004) and more commonly African-American (White: 66.2% vs. 78.3%, African-American: 31.3% vs. 20.7%; p = 0.009). On regression, ADI block was an independent predictor (odds ratio [OR] = 1.013, 95% confidence interval [CI] 1.002-1.024; p = 0.024) of high-risk PCa at diagnosis, whereas race was not (OR = 1.312, 95% CI 0.782-2.201; p = 0.848). A separate regression demonstrated higher ADI (OR = 1.016, 95% CI 1.004-1.027; p = 0.006) and older age (OR = 1.083, 95% CI 1.054-1.114; p < 0.001) were independent predictors for high-risk PCa. Findings, depicted in heatmaps, demonstrated the geographic locations where men with PCa were predicted to have high-risk disease based on their age and SES. Socioeconomic status was more closely associated with high-risk PCa at diagnosis than race. Although, of any variable, age was most predictive. The heatmaps identified areas that would benefit from increased awareness, education, and screening to facilitate an earlier PCa diagnosis.
Identifiants
pubmed: 39080130
doi: 10.1245/s10434-024-15675-1
pii: 10.1245/s10434-024-15675-1
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. Society of Surgical Oncology.
Références
Henley SJ, Ward EM, Scott S, et al. Annual report to the nation on the status of cancer, part I: National cancer statistics. Cancer. 2020;126(10):2225–49. https://doi.org/10.1002/cncr.32802 .
doi: 10.1002/cncr.32802
pubmed: 32162336
Cancer Stat Facts: Prostate Cancer. National Cancer Institute. Surveillance, Epidemiology, and End Results Program.
Brawley OW. Trends in prostate cancer in the United States. J Natl Cancer Inst Monogr. 2012;45:152–6. https://doi.org/10.1093/jncimonographs/lgs035 .
doi: 10.1093/jncimonographs/lgs035
Carrol L. More men diagnosed with advanced prostate cancer as PSA screening declines. Published online January 12, 2023.
Prostate Cancer Statistics. Division of Cancer Prevention and Control, Centers for Disease Control and Prevention.
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33. https://doi.org/10.3322/caac.21708 .
doi: 10.3322/caac.21708
pubmed: 35020204
Grossman DC, Curry SJ, Owens DK, et al. Screening for prostate cancer USPreventive servicestaskforcerecommendation statement. JAMA. 2018;319(18):1901–13. https://doi.org/10.1001/jama.2018.3710 .
doi: 10.1001/jama.2018.3710
pubmed: 29801017
Jemal A, Fedewa SA, Ma J, et al. Prostate cancer incidence and psa testing patterns in relation to uspstf screening recommendations. JAMA. 2015;314(19):2054–61. https://doi.org/10.1001/jama.2015.14905 .
doi: 10.1001/jama.2015.14905
pubmed: 26575061
Moyer V. Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2012;157(2):1.
doi: 10.7326/0003-4819-157-2-201207170-00459
Magnani CJ, Li K, Seto T, et al. Changes in Prostate Specific Antigen Screening and Prostate Cancer Diagnosis After Guideline Changes. J Urol. 2018;199:1.
doi: 10.1016/j.juro.2018.02.1270
Halpern JA, Shoag JE, Artis AS, et al. National trends in prostate biopsy and radical prostatectomy volumes following the us preventive services task force guidelines against prostate-specific antigen screening. JAMA Surg. 2017;152(2):192–8. https://doi.org/10.1001/jamasurg.2016.3987 .
doi: 10.1001/jamasurg.2016.3987
pubmed: 27806151
Filippou P, Pruthi RS. Trends in prostate cancer screening following changes made by the US preventive services task force: Are we turning back the clock? JAMA Surg. 2017;142(2):1.
Shenoy D, Packianathan S, Chen AM, Vijayakumar S. Do African-American men need separate prostate cancer screening guidelines? BMC Urol. 2016;16(1):1. https://doi.org/10.1186/s12894-016-0137-7 .
doi: 10.1186/s12894-016-0137-7
Siegel DA, O’Neil ME, Richards TB, Dowling NF, Weir HK. Prostate cancer incidence and survival, by stage and race/ethnicity-United States, 2001–2017. Centers Dis Control Prev Morbid Mortal Weekly Rep. 2020;69(41):1.
Bernstein AN, Shoag JE, Golan R, et al. Contemporary incidence and outcomes of prostate cancer lymph node metastases. J Urol. 2018;199(6):1510–7. https://doi.org/10.1016/j.juro.2017.12.048 .
doi: 10.1016/j.juro.2017.12.048
pubmed: 29288121
Loeb S. Will changes to prostate cancer screening guidelines preserve benefits and reduce harm? Eur Urol. 2017;71(1):66–7. https://doi.org/10.1016/J.EURURO.2016.04.002 .
doi: 10.1016/J.EURURO.2016.04.002
pubmed: 27090973
Weiner AB, Matulewicz RS, Eggener SE, Schaeffer EM. Increasing incidence of metastatic prostate cancer in the United States (2004–2013). Prostate Cancer Prostatic Dis. 2016;19(4):395–7. https://doi.org/10.1038/pcan.2016.30 .
doi: 10.1038/pcan.2016.30
pubmed: 27431496
Desai MM, Cacciamani GE, Gill K, et al. Trends in Incidence of Metastatic Prostate Cancer in the US. JAMA Netw Open. 2022. https://doi.org/10.1001/jamanetworkopen.2022.2246 .
doi: 10.1001/jamanetworkopen.2022.2246
pubmed: 36542380
pmcid: 9857175
Shoag J, Sedrakyan A, Halpern J, Hsu WC, Hu J. Increase in the incidence of advanced prostate cancer in the United States. J Urol. 2017;197:1.
doi: 10.1016/j.juro.2017.02.479
Hu JC, Nguyen P, Mao J, et al. Increase in prostate cancer distant metastases at diagnosis in the United States. JAMA Oncol. 2017;3(5):705–7. https://doi.org/10.1001/jamaoncol.2016.5465 .
doi: 10.1001/jamaoncol.2016.5465
pubmed: 28033446
Shoag JE, Mittal S, Hu JC. Reevaluating PSA testing rates in the PLCO trial. N Engl J Med. 2016;374(18):1.
doi: 10.1056/NEJMc1515131
Gulati R, Tsodikov A, Etzioni R, et al. Expected population impacts of discontinued prostate-specific antigen screening. Cancer. 2014;120(22):3519–26. https://doi.org/10.1002/cncr.28932 .
doi: 10.1002/cncr.28932
pubmed: 25065910
Kelly SP, Anderson WF, Rosenberg PS, Cook MB. Past, current, and future incidence rates and burden of metastatic prostate cancer in the United States. Eur Urol Focus. 2018;4(1):121–7. https://doi.org/10.1016/j.euf.2017.10.014 .
doi: 10.1016/j.euf.2017.10.014
pubmed: 29162421
Badal S, Aiken W, Morrison B, et al. Disparities in prostate cancer incidence and mortality rates: Solvable or not? Prostate. 2020;80(1):3–16. https://doi.org/10.1002/pros.23923 .
doi: 10.1002/pros.23923
pubmed: 31702061
Jani C, Mouchati C, Abdallah N, et al. Trends in prostate cancer mortality in the United States of America, by state and race, from 1999 to 2019: estimates from the centers for disease control WONDER database. Prostate Cancer Prostatic Dis. 2023;26(3):552–62. https://doi.org/10.1038/s41391-022-00628-0 .
doi: 10.1038/s41391-022-00628-0
pubmed: 36522462
Powell IJ. Epidemiology and pathophysiology of prostate cancer in African-American men. J Urol. 2007;177(2):444–9. https://doi.org/10.1016/j.juro.2006.09.024 .
doi: 10.1016/j.juro.2006.09.024
pubmed: 17222606
Lin J, Rodriguez S, Zhou H, Sparks AD, Simmens SJ, Amdur RL. Racial disparities in late-stage prostate cancer: A SEER database analysis 2005–2015. J Clin Oncol (2019)
Hoffman RM, Gilliland FD, Eley JW, et al. Racial and Ethnic Differences in Advanced-Stage Prostate Cancer: The Prostate Cancer Outcomes Study; 2001. https://academic.oup.com/jnci/article/93/5/388/2906486
Taksler GB, Keating NL, Cutler DM. Explaining racial differences in prostate cancer mortality. Cancer. 2012;118(17):4280–9. https://doi.org/10.1002/cncr.27379 .
doi: 10.1002/cncr.27379
pubmed: 22246942
Cuevas AG, Trudel-Fitzgerald C, Cofie L, Zaitsu M, Allen J, Williams DR. Placing prostate cancer disparities within a psychosocial context: challenges and opportunities for future research. Cancer Causes Control. 2019. https://doi.org/10.1007/s10552-019-01159-1 .
doi: 10.1007/s10552-019-01159-1
pubmed: 30903484
pmcid: 6484832
Smith ZL, Eggener SE, Murphy AB. African-American Prostate Cancer Disparities. Curr Urol Rep. 2017;18(10):1. https://doi.org/10.1007/s11934-017-0724-5 .
doi: 10.1007/s11934-017-0724-5
Dess RT, Hartman HE, Mahal BA, et al. Association of black race with prostate cancer-specific and other-cause mortality. JAMA Oncol. 2019;5(7):975–83. https://doi.org/10.1001/jamaoncol.2019.0826 .
doi: 10.1001/jamaoncol.2019.0826
pubmed: 31120534
pmcid: 6547116
Baker E. Socioeconomic status, definition. In The Wiley Blackwell Encyclopedia of Health, Illness, Behavior, and Society [Internet]. Wiley (2014).
Kind A, Buckingham W. Making neighborhood disadvantage metrics accessible: the neighborhood atlas. N Engl J Med. 2018;378:1.
doi: 10.1056/NEJMp1802313
Hanchett TW. Sorting out the New South City: race, class, and urban development in Charlotte, 1875–1975. Second: The University of North Carolina Press; 2020.
Xie M, Gao XS, Ma MW, et al. Population-based comparison of different risk stratification systems among prostate cancer patients. Front Oncol. 2021;11:1. https://doi.org/10.3389/fonc.2021.646073 .
doi: 10.3389/fonc.2021.646073
Delahunt B, Miller RJ, Srigley JR, Evans AJ, Samaratunga H. Gleason grading: past, present and future. Histopathology. 2012;60(1):75–86. https://doi.org/10.1111/j.1365-2559.2011.04003.x .
doi: 10.1111/j.1365-2559.2011.04003.x
pubmed: 22212079
Mohler JL, Antonarakis ES. NCCN Guidelines Updates: Management of Prostate Cancer. J Natl Compr Canc Netw. 2019;17(55):583–6. https://doi.org/10.6004/jnccn.2019.5011 .
doi: 10.6004/jnccn.2019.5011
pubmed: 31117038
Census Blocks and Block Groups. Census.gov.
Neighborhood Atlas. Centers for Health Disparities Research: University of Wisconsin School of Medicine and Public Health.
Pinsky PF, Prorok PC, Yu K, et al. Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years. Cancer. 2017;123(4):592–9. https://doi.org/10.1002/cncr.30474 .
doi: 10.1002/cncr.30474
pubmed: 27911486
Andriole GL, Crawford ED, Grubb RL, et al. Prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian cancer screening trial: mortality results after 13 years of follow-up. J Natl Cancer Inst. 2012;104(2):125–32. https://doi.org/10.1093/jnci/djr500 .
doi: 10.1093/jnci/djr500
pubmed: 22228146
pmcid: 3260132
Gaylis F, Choi J, Dato P, et al. The change in prostate cancer presentation and diagnosis coinciding with screening recommendations. J Urol. 2016;195(4S):1.
doi: 10.1016/j.juro.2016.02.2293
Johns LE, Houlston RS. A systematic review and meta-analysis of familial prostate cancer risk. BJU Int. 2003;91(9):789–94. https://doi.org/10.1046/j.1464-410X.2003.04232.x .
doi: 10.1046/j.1464-410X.2003.04232.x
pubmed: 12780833
Telang JM, Lane BR, Cher ML, Miller DC, Dupree JM. Prostate cancer family history and eligibility for active surveillance: a systematic review of the literature. BJU Int. 2017;120(4):464–7. https://doi.org/10.1111/bju.13862 .
doi: 10.1111/bju.13862
pubmed: 28371016
Selkirk CG, Wang CH, Lapin B, Helfand BT. Family history of prostate cancer in men being followed by active surveillance does not increase risk of being diagnosed with high-grade disease. Urology. 2015;85(4):742–7. https://doi.org/10.1016/j.urology.2014.10.060 .
doi: 10.1016/j.urology.2014.10.060
pubmed: 25709045
Bruner DW, Moore D, Parlanti A, Dorgan J, Engstrom P. Relative risk of prostate cancer for men with affected relatives: Systematic review and meta-analysis. Int J Cancer. 2003;107(5):797–803. https://doi.org/10.1002/ijc.11466 .
doi: 10.1002/ijc.11466
pubmed: 14566830
Madersbacher S, Alcaraz A, Emberton M, et al. The influence of family history on prostate cancer risk: Implications for clinical management. BJU Int. 2011;107(5):716–21. https://doi.org/10.1111/j.1464-410X.2010.10024.x .
doi: 10.1111/j.1464-410X.2010.10024.x
pubmed: 21166744